Alamar Biosciences, Inc.(ALMR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALMR Alamar Biosciences, Inc.

交易中 10-01 13:02:14 EDT

33.38

-0.69

-2.03%

最高34.67	最低32.94	成交量12.88万
今开33.92	昨收34.07	日振幅5.06%
总市值23.14亿	流通市值4.32亿	总股本6,931万
成交额437.06万	换手率1.00%	流通股本1,294万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALMR","market":"US","secType":"STK","nameCN":"Alamar Biosciences, Inc.","latestPrice":33.38,"timestamp":1790874133447,"preClose":34.07,"halted":0,"volume":128844,"delay":0,"changeRate":-0.02025242148517751,"floatShares":12937500,"shares":69311200,"eps":-0.716,"marketStatus":"交易中","change":-0.69,"latestTime":"10-01 13:02:14 EDT","open":33.92,"high":34.665,"low":32.94,"amount":4370595.145776,"amplitude":0.050631,"askPrice":33.52,"askSize":102,"bidPrice":33.18,"bidSize":26,"shortable":3,"etf":0,"ttmEps":-0.716,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":34.07,"preHourTrading":{"tag":"盘前","latestPrice":34.07,"preClose":34.07,"latestTime":"09:22 EDT","volume":30151,"amount":1027294.138244,"timestamp":1790860929179,"change":0,"changeRate":0,"amplitude":0.056026},"postHourTrading":{"tag":"盘后","latestPrice":34.07,"preClose":34.07,"latestTime":"19:30 EDT","volume":4960,"amount":168991.7788,"timestamp":1790811003866,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.409336},"requestUrl":"/m/hq/s/ALMR","defaultTab":"news","newsList":[{"id":"1165363440","title":"Alamar Biosciences携手阿尔茨海默病数据倡议与Gates Ventures，深化全球合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1165363440","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165363440?lang=zh_cn&edition=full","pubTime":"2026-08-11 04:05","pubTimestamp":1786392312,"startTime":"0","endTime":"0","summary":"Alamar Biosciences（简称：ALMR）正积极拓展其全球战略版图，与阿尔茨海默病数据倡议（Alzheimer’s Disease Data Initiative）以及Gates Ventures达成更广泛的合作伙伴关系。这一举措，旨在通过数据共享与技术协同，加速对阿尔茨海默病的研究与疗法开发。合作方将整合各自资源，推动全球范围内的疾病数据整合与创新诊断工具的应用。Alamar Biosciences的管理层表示，此合作将进一步提升其平台在神经退行性疾病领域的应用潜力，为患者群体带来更精准的诊断方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130899284","title":"财报前瞻｜Alamar Biosciences, Inc.本季度营收预计约2,593.98万美元，机构观点偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1130899284","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130899284?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:55","pubTimestamp":1785718537,"startTime":"0","endTime":"0","summary":"Alamar Biosciences, Inc.将于2026年08月10日盘后发布2026年第二季度财报，市场聚焦收入延续性与亏损收窄节奏。市场一致预期显示，本季度Alamar Biosciences, Inc.营收预计为2,593.98万美元，同比增速记录为0.00%；调整后每股收益预计为—0.33美元，同比增速记录为0.00%，公司层面暂未披露本季度的毛利率与净利率指引，亦未提供本季度收入指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Alamar Biosciences, Inc.本季度营收预计约2,593.98万美元，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120675244","title":"Alzpath 扩大与 Alamar Biosciences 的战略合作，推动阿尔茨海默病临床诊断进步","url":"https://stock-news.laohu8.com/highlight/detail?id=1120675244","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120675244?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:35","pubTimestamp":1784810143,"startTime":"0","endTime":"0","summary":"Alzpath 宣布，已进一步扩展与 Alamar Biosciences 的战略合作协议。双方旨在携手推进阿尔茨海默病的临床诊断技术。通过此次深化合作，Alzpath 将充分利用 Alamar Biosciences 的创新平台，加速相关诊断工具的开发与应用。这一举措有望为阿尔茨海默病的早期检测与精准诊断带来显著突破，从而更好地满足患者和医疗系统的迫切需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMR","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111524499","title":"Alamar Biosciences推出首个基于血液的Emtbr-tau多重免疫检测方法，该标志物为阿尔茨海默病研究最重要生物标志物之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1111524499","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111524499?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:16","pubTimestamp":1783430177,"startTime":"0","endTime":"0","summary":"Alamar Biosciences推出了首个基于血液的Emtbr-tau多重免疫检测方法。Emtbr-tau是阿尔茨海默病研究领域最为关键的生物标志物之一。这一创新检测方案的问世，标志着在利用血液样本进行神经退行性疾病精准诊断方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180385750","title":"美银全球研究开始覆盖Alamar Biosciences，给予中性评级及27美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180385750","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180385750?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:51","pubTimestamp":1778586675,"startTime":"0","endTime":"0","summary":"美银全球研究（BofA Global Research）已开始对生物科技公司Alamar Biosciences进行跟踪研究，并在其首份报告中给予该公司“中性”评级。与此同时，分析师为该股设定了27美元的目标价位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147513482","title":"Leerink Partners首予Alamar Biosciences“跑赢大盘”评级，目标价35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1147513482","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147513482?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:07","pubTimestamp":1778580462,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布，首次覆盖生物科技公司Alamar Biosciences，并给予其“跑赢大盘”的评级。该机构为该公司设定了35美元的目标股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186885979","title":"异动解读 | Alamar Biosciences IPO后受技术优势及投资者信心推动，盘中大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186885979","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186885979?lang=zh_cn&edition=full","pubTime":"2026-04-20 22:16","pubTimestamp":1776694619,"startTime":"0","endTime":"0","summary":"Alamar Biosciences, Inc.（股票代码：ALMR）今日盘中股价大幅上涨5.00%，市场表现强劲。消息面上，该公司于近期成功登陆纳斯达克，完成首次公开募股（IPO）。作为精准蛋白质组学领域的领导者，Alamar Biosciences自主研发的NULISA™技术平台在蛋白质检测方面具有超高灵敏度与特异性，其ARGO™ HT全自动高通量设备也已实现广泛的市场渗透，累计装机量超过100台，客户遍布全球25个国家。此外，知名风险投资机构启明创投作为公司重要的早期投资方，持续多轮支持其发展，并在IPO前持有约19.2%的股份，这进一步增强了市场对该公司长期成长潜力的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628716309","title":"精准蛋白质组学领域领导者Alamar Biosciences成功登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2628716309","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628716309?lang=zh_cn&edition=full","pubTime":"2026-04-20 10:28","pubTimestamp":1776652080,"startTime":"0","endTime":"0","summary":"上海2026年4月20日 /美通社/ -- 北京时间2026年4月17日，启明创投投资企业、精准蛋白质组学领域领导者Alamar Biosciences成功登陆纳斯达克，至此启明创投迎来开年第五个IPO。2020年，启明创投领投了Alamar Biosciences的A轮融资，并在B轮和C轮继续支持公司发展。IPO前启明创投持有Alamar Biosciences约19.2%的股份，是公司最重要的机构投资方之一。Alamar Biosciences成立于2018年，该公司致力于开发并商业化蛋白质组学技术，树立蛋白质检测与分析领域的金标准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4937755_ZH37755_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4937755_ZH37755_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["GPIQ","QQQY","QDTE","QQQ","TQQY","SQQQ","QQQA","TQQQ","QLD","QYLG","QQQJ","ONEQ","BK4007","BK1147","NQmain","QQQE","QID","IYW","MNQmain","FTEC","NVIW.SI","JEPQ","PSQ","ALMR","QQQM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628665157","title":"生物医药企业Alamar纳斯达克上市：市值14亿美元 年亏2982万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628665157","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628665157?lang=zh_cn&edition=full","pubTime":"2026-04-19 15:39","pubTimestamp":1776584368,"startTime":"0","endTime":"0","summary":"精准蛋白质组学领域Alamar Biosciences（股票代码为“ALMR”）日前在美国纳斯达克上市。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391220993276710514400681.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391220993276710514400681.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33339/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["QQQE","QQQ","PSQ","QDTE","ONEQ","BK4585","BK4588","BK4007","QQQY","QQQJ","BK4581","FTEC","QQQM","TQQQ","GPIQ","QYLG","TQQY","QQQA","IYW","NVIW.SI","JEPQ","QID","SQQQ","NQmain","QLD","ALMR","BK1147","MNQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107620656","title":"异动解读 | IPO首秀开盘价高于发行价，Alamar Biosciences盘中大涨32.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107620656","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107620656?lang=zh_cn&edition=full","pubTime":"2026-04-18 00:37","pubTimestamp":1776443855,"startTime":"0","endTime":"0","summary":"Alamar Biosciences, Inc.（股票代码：ALMR）今日盘中股价大幅上涨32.94%，引起了市场的广泛关注。消息面上，该公司今日在纳斯达克首次公开募股（IPO）上市。其股票发行价为每股17美元，而市场预计的开盘价达到22.50美元，显著高于发行价。此次IPO以发行区间上限价格出售了约1130万股股票，成功募集资金约1.913亿美元。Alamar Biosciences是一家专注于蛋白质组学的公司，开发了用于检测血液中低水平蛋白质生物标记物的仪器平台，该技术为疾病研究和诊断提供了有力工具。市场对其技术和增长前景的乐观情绪，推动了上市首日的强劲表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628783908","title":"美股异动 | Alamar Biosciences(ALMR.US)登陆美股市场 开盘涨超34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628783908","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628783908?lang=zh_cn&edition=full","pubTime":"2026-04-18 00:07","pubTimestamp":1776442021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，Alamar Biosciences(ALMR.US)登陆美股市场，开盘涨超34%，报22.91美元。IPO价格为17美元。Alamar Biosciences是一家总部位于美国加州的生物科技公司，专注于精准蛋白质组学技术的开发与应用。公司核心产品基于自研的NULISA平台，能够以极高灵敏度检测血液中的微量蛋白质标志物，从而帮助科研人员更早发现疾病、推动药物研发和精准医疗发展。其技术主要应用于阿尔茨海默症、帕金森等神经退行性疾病研究领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ALMR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alamarbio.com","stockEarnings":[{"period":"1week","weight":0.06},{"period":"1month","weight":0.1156},{"period":"3month","weight":0.3134},{"period":"6month","weight":1.0041},{"period":"ytd","weight":1.0041}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alamar Biosciences, Inc.于2018年5月7日在特拉华州注册成立，总部位于加利福尼亚州弗里蒙特市。该公司是一家商业化阶段的蛋白质组学公司，致力于建立蛋白质检测和分析的黄金标准。公司提供专有的NULISA平台，该平台能够以超高灵敏度、高特异性、灵活的多重检测、宽动态范围和自动化，检测非侵入性生物体液中的低丰度蛋白质生物标志物，从而实现“精准蛋白质组学”。公司提供仪器、耗材和分析软件的集成解决方案，用于发现、转化研究和诊断开发。","exchange":"NASDAQ","name":"Alamar Biosciences, Inc.","nameEN":"Alamar Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alamar Biosciences, Inc.(ALMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alamar Biosciences, Inc.(ALMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alamar Biosciences, Inc.,ALMR,Alamar Biosciences, Inc.股票,Alamar Biosciences, Inc.股票老虎,Alamar Biosciences, Inc.股票老虎国际,Alamar Biosciences, Inc.行情,Alamar Biosciences, Inc.股票行情,Alamar Biosciences, Inc.股价,Alamar Biosciences, Inc.股市,Alamar Biosciences, Inc.股票价格,Alamar Biosciences, Inc.股票交易,Alamar Biosciences, Inc.股票购买,Alamar Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alamar Biosciences, Inc.(ALMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alamar Biosciences, Inc.(ALMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}